'What Else Don't We Know?' May Spread Beyond Valeant
This article was originally published in Scrip
Executive Summary
The day after a damning report from short-selling firm Citron Research sent shares of Valeant Pharmaceuticals International Inc. into tailspin, diving 40%, the stock spiraled down again, plunging 20% – this time pushed off the cliff by BMO Nesbitt Burns Inc. analyst Alex Arfaei, who started off the day by asking "What else is out there that we don't know?"